(Q37952110)

25 August 2017

title

Carcinomas of an unknown primary origin--diagnosis and treatment (English)

1 reference

25 August 2017

3

Karim Fizazi

1 reference

25 August 2017

Christophe Massard

1

1 reference

25 August 2017

Yohann Loriot

series ordinal

2

1 reference

25 August 2017

language of work or name

English

0 references

publication date

1 November 2011

1 reference

Nature Reviews Clinical Oncology

25 August 2017

published in

1 reference

25 August 2017

volume

8

1 reference

25 August 2017

issue

12

1 reference

25 August 2017

page(s)

701-710

1 reference

Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Carcinoma of unknown primary (CUP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Metastases in carcinoma; analysis of 1000 autopsied cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Switching benchmarks in cancer of unknown primary: from autopsy to microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Treatment for patients with unknown primary cancer and favorable prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Diagnostic and therapeutic management of cancer of an unknown primary

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Pathologic evaluation of unknown primary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Diagnostic strategies for unknown primary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Keratin expression in human tissues and neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Multiclass cancer diagnosis using tumor gene expression signatures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin’s lymphoma and Hodgkin’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Role of 18F-FDG PET-CT imaging for the detection of an unknown primary tumour: preliminary results in 21 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Detection of unknown occult primary tumors using positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Unknown primary tumors: detection with dual-modality PET/CT--initial experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Treatment of patients with specific subsets of carcinoma of an unknown primary site

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Prognostic factors in unknown primary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Cancer of unknown primary patients with midline nodal distribution: Midway between poor and favourable prognosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Elevated germ cell markers in carcinoma of uncertain primary site do not predict response to platinum based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Beyond chemotherapy: targeted therapies in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Breast carcinoma presenting as axillary metastases without evidence of a primary tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Cervical lymph node metastases of squamous cell carcinoma from an unknown primary

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Treatment with cisplatin and etoposide in patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Neuroendocrine carcinoma of unknown primary site

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Neuroendocrine carcinoma of unknown primary: a systematic review of the literature and a comparative study with other neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Metastatic inguinal nodes from an unknown primary neoplasm. A review of 56 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Molecular classification of unknown primary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Targeting c-KIT, PDGFR in cancer of unknown primary: a screening study for molecular markers of benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Added value of molecular targeted agents in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Perspectives for targeted therapies in cancer of unknown primary site

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

A randomized Phase II trial in patients with carcinoma of an unknown primary site

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Mitomycin C, epirubicin and cisplatin versus mitomycin C alone as therapy for carcinoma of unknown primary origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primary

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Safety and efficacy of a combination of docetaxel and cisplatin in patients with unknown primary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Epidemiology of unknown primary tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Molecular Profiling of a Tumor of Unknown Origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Metastatic carcinomas from occult primary tumors. A study of 254 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Neoplasms of unknown primary site: a clinicopathological study of autopsied patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Adenocarcinoma of unknown primary site. The Brooke Army Medical Center experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Therapy of adenocarcinoma of unknown primary: are we making progress?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Utility of Breast Magnetic Resonance Imaging in Patients With Occult Primary Breast Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Hormone receptor studies in axillary metastases from occult breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Poorly differentiated carcinoma of unknown primary site: correlation of light microscopic findings with response to cisplatin-based combination chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Occult breast carcinoma presenting as axillary metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Carcinomas of an unknown primary site: a curable disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.158

Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium

31 March 2020

1 reference

12 December 2020

Molecular classification of human carcinomas by use of gene expression signatures.

1 reference

12 December 2020

Diagnostic evaluation of patients with carcinoma of unknown primary tumor site

1 reference

12 December 2020

Undifferentiated tumor: true identity by immunohistochemistry

1 reference

12 December 2020

Surgical and ablative treatment for metastatic adenocarcinoma to the liver from unknown primary tumor.

1 reference

12 December 2020

Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach.

1 reference

12 December 2020

The role of nuclear medicine in the diagnosis of cancer of unknown origin.

1 reference

12 December 2020

Cancer of unknown primary: biological and clinical characteristics.

1 reference

12 December 2020

FDG PET detection of unknown primary tumors

1 reference

12 December 2020

MRI and breast cancer: role in detection, diagnosis, and staging.

1 reference

12 December 2020

Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay.

1 reference

12 December 2020

PET/CT today and tomorrow

1 reference

12 December 2020

Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma

1 reference

12 December 2020

Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.

1 reference

12 December 2020

Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors.

1 reference

12 December 2020

10.1038/NRCLINONC.2011.158

Identifiers

DOI

1 reference

25 August 2017

1 reference